ARCT vs REGN: Which Stock is Better?
Side-by-side comparison of Arcturus Therapeutics Holdings Inc and Regeneron Pharmaceuticals Inc in 2026
ARCT
Arcturus Therapeutics Holdings Inc
$6.39
REGN
Regeneron Pharmaceuticals Inc
$759.05
Key Metrics Comparison
| Metric | ARCT | REGN | Winner |
|---|---|---|---|
| Market Cap | $181.62M | $80.02B | REGN |
| P/E Ratio | N/A | 18.25 | REGN |
| EPS (TTM) | $N/A | $41.48 | REGN |
| Revenue Growth | -0.7% | 0.0% | REGN |
| Gross Margin | -36.8% | 44.6% | REGN |
Analyze ARCT
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ARCT or REGN a better investment?
Comparing ARCT and REGN: Arcturus Therapeutics Holdings Inc has a market cap of $181.62M while Regeneron Pharmaceuticals Inc has $80.02B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ARCT and REGN?
ARCT (Arcturus Therapeutics Holdings Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ARCT or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ARCT or REGN?
REGN has higher revenue growth at 0.0% vs -0.7% for ARCT.
Which company is more profitable: ARCT or REGN?
Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 44.6% compared to -36.8% for ARCT.
Which is the larger company: ARCT or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $80.02B compared to $181.62M for ARCT.
Should I buy ARCT or REGN in 2026?
Both ARCT and REGN have investment merit. ARCT trades at $6.39 while REGN trades at $759.05. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ARCT and REGN stock?
Key differences: Market Cap ($181.62M vs $80.02B), P/E Ratio (N/A vs 18.2x), Revenue Growth (-0.7% vs 0.0%), Gross Margin (-36.8% vs 44.6%).